Island Pharmaceuticals Reports Q1 FY26 Activities and Cash Flow
Island Pharmaceuticals finalized its acquisition of the antiviral asset Galidesivir from BioCryst Pharmaceuticals, Inc., thereby significantly expanding its pipeline. It engaged with the U.S. Food and Drug Administration via a Type C meeting request under its open IND to explore approval under the “Animal Rule” pathway with feedback expected by 12 November 2025 (US time). The historical data included very promising non-human primate survival rates (94% survival in Marburg-infected primates compared to 0% in placebo).
Island Pharmaceuticals Reports Q1 FY26 Activities and Cash Flow